

1614

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-178US

In Re Application Of: Kumar et al.

COPY OF PAPERS
ORIGINALLY FILED

FEB 26 2002

Serial No. 09/888,268	Filing Date 6/22/2001	Examiner unknown	Group Art Unit 1614
--------------------------	--------------------------	---------------------	------------------------

Title: BIOAVAILABLE DOSAGE FORM OF LORATADINE

RECEIVED

MAR -4 2002

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
 (Under 37 CFR 1.97(b) & 1.97(c))

Docket No.
RLL-178US

In Re Application: **Kumar et al.**

**COPY OF PAPERS
 ORIGINALLY FILED**

FEB 26 2002

PATENT & TRADEMARK OFFICE

Serial No.
09/888,268

Filing Date
6/22/2001

Examiner
unknown

Group Art Unit
1614

BIOAVAILABLE DOSAGE FORM OF LORATADINE

RECEIVED

MAR 4 2002

TECH CENTER 1600/2900

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. _____ as described below. A duplicate copy of this sheet is enclosed.
 - Charge the amount of _____
 - Credit any overpayment.
 - Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____) on _____

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on February 5, 2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Christine Kennedy

Signature of Person Mailing Correspondence

Christine Kennedy

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Jayadeep R. Deshmukh, Esq.

Reg. No. 34,507

Ranbaxy Pharmaceuticals Inc.

600 College Road East, Suite 2100

Princeton, New Jersey 08540

Telephone: (609) 720-5608

Facsimile: (609) 514-9779

CC:

Dated: **February 4, 2002**